These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16303728)

  • 1. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
    Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
    Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW; Ose L; Marais AD
    J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
    Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.